ClinConnect ClinConnect Logo
Search / Trial NCT06347874

Cryo Rib Fracture Study

Launched by UNIVERSITY OF MINNESOTA · Apr 2, 2024

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

The Cryo Rib Fracture Study is looking at a new way to help people with rib fractures manage their pain. Researchers want to find out if a treatment called cryoablation, which uses cold to numb the nerves between the ribs, is more effective in reducing pain after 7 days compared to a different method using an ESP catheter. This study is currently recruiting participants who are 18 years or older and have more than one broken rib.

If you or a loved one has multiple rib fractures and are interested in participating, you should be aware that certain conditions might prevent eligibility. For example, if you have issues with regional anesthesia, are pregnant, or have specific allergies to cold, you may not qualify. Participants in the study will receive either the cryoablation treatment or the ESP catheter and will be monitored for pain relief over the week following the procedure. This study aims to improve pain management for those suffering from rib injuries, so your involvement could help advance knowledge in this area.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients who are over 18 who have more than one ribs fractured.
  • Exclusion Criteria:
  • Patients who have an exclusion to regional anesthesia.
  • Patients who are pregnant via self-report or pregnancy test if they take one.
  • Non-English speakers
  • Patients who have cold urticaria
  • Patients with bilateral fractures
  • Patients currently intubated

About University Of Minnesota

The University of Minnesota is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on interdisciplinary collaboration, the university leverages its extensive resources and expertise to conduct cutting-edge studies aimed at improving patient outcomes and addressing critical health challenges. Its robust clinical trial program emphasizes ethical standards, patient safety, and scientific rigor, contributing to the development of novel therapies and interventions that enhance medical practice and public health.

Locations

Minneapolis, Minnesota, United States

Patients applied

0 patients applied

Trial Officials

Neil Hanson

Principal Investigator

University of Minnesota

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported